AFT Pharmaceuticals Limited develops, licenses, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally. More Details
High growth potential with adequate balance sheet.
Share Price & News
How has AFT Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AFT has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AFT exceeded the NZ Pharmaceuticals industry which returned -23.3% over the past year.
Return vs Market: AFT exceeded the NZ Market which returned 6.7% over the past year.
Price Volatility Vs. Market
How volatile is AFT Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHere's Why We Don't Think AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings Reflect Its Underlying Earnings Potential
1 month ago | Simply Wall StWhat Kind Of Investors Own Most Of AFT Pharmaceuticals Limited (NZSE:AFT)?
1 month ago | Simply Wall StWhat Can We Learn About AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation?
Is AFT Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AFT (NZ$4.88) is trading below our estimate of fair value (NZ$8.98)
Significantly Below Fair Value: AFT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AFT is poor value based on its PE Ratio (40.6x) compared to the XO Pharmaceuticals industry average (39x).
PE vs Market: AFT is poor value based on its PE Ratio (40.6x) compared to the NZ market (23.1x).
Price to Earnings Growth Ratio
PEG Ratio: AFT is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: AFT is overvalued based on its PB Ratio (73.5x) compared to the XO Pharmaceuticals industry average (3.9x).
How is AFT Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AFT's forecast earnings growth (36.6% per year) is above the savings rate (2.6%).
Earnings vs Market: AFT's earnings (36.6% per year) are forecast to grow faster than the NZ market (11.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AFT's revenue (16.9% per year) is forecast to grow faster than the NZ market (5.5% per year).
High Growth Revenue: AFT's revenue (16.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AFT's Return on Equity is forecast to be very high in 3 years time (43.1%).
How has AFT Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AFT has a large one-off gain of NZ$9.8M impacting its March 31 2020 financial results.
Growing Profit Margin: AFT became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: AFT has become profitable over the past 5 years, growing earnings by 38.2% per year.
Accelerating Growth: AFT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AFT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (117.8%).
Return on Equity
High ROE: Whilst AFT's Return on Equity (73.56%) is outstanding, this metric is skewed due to their high level of debt.
How is AFT Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AFT's short term assets (NZ$55.3M) exceed its short term liabilities (NZ$25.1M).
Long Term Liabilities: AFT's short term assets (NZ$55.3M) exceed its long term liabilities (NZ$44.7M).
Debt to Equity History and Analysis
Debt Level: AFT's debt to equity ratio (250.4%) is considered high.
Reducing Debt: AFT's debt to equity ratio has reduced from 1009.2% to 250.4% over the past 5 years.
Debt Coverage: AFT's debt is well covered by operating cash flow (34.4%).
Interest Coverage: AFT's interest payments on its debt are not well covered by EBIT (1.7x coverage).
What is AFT Pharmaceuticals's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AFT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AFT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AFT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AFT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AFT's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Hartley Atkinson, M.Pharm (Dist), PhD, founded AFT Pharmaceuticals Limited in 1997, has been its Chief Executive Officer since September 04, 1997 and also serves as its Managing Director. Before establ ...
CEO Compensation Analysis
Compensation vs Market: Hartley's total compensation ($USD394.35K) is below average for companies of similar size in the NZ market ($USD588.56K).
Compensation vs Earnings: Hartley's compensation has been consistent with company performance over the past year.
|Chief of Staff & Executive Director||8.08yrs||NZ$130.49k||no data|
|CFO & Company Secretary||no data||no data||0% |
|Group Marketing Manager||no data||no data||no data|
|Head of Drug Development||no data||no data||no data|
|General Manager of AFT Australia||no data||no data||no data|
|General Manager of Promoted Products Australasia & South East Asia||no data||no data||no data|
|Director of International Business||2.92yrs||no data||no data|
Experienced Management: AFT's management team is seasoned and experienced (8.1 years average tenure).
|Chief of Staff & Executive Director||8.08yrs||NZ$130.49k||no data|
|Independent Director||5.08yrs||NZ$93.13k||0.12% |
|Independent Chairman||5.33yrs||NZ$100.00k||0.17% |
|Independent Director||8.08yrs||NZ$47.50k||0.054% |
|Independent Director||8.08yrs||NZ$55.00k||0.24% |
Experienced Board: AFT's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.5%.
AFT Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
- Name: AFT Pharmaceuticals Limited
- Ticker: AFT
- Exchange: NZSE
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NZ$510.345m
- Shares outstanding: 104.58m
- Website: https://www.aftpharm.com
Number of Employees
- AFT Pharmaceuticals Limited
- 129 Hurstmere Road
- Level 1
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AFT||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Dec 2015|
|AFP||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2015|
|AFP||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2015|
AFT Pharmaceuticals Limited develops, licenses, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally. The company offers approximately 130 prescription and non-p ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/29 10:33|
|End of Day Share Price||2020/10/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.